AHA Announces Last Minute Scientific Programming To Be Presented At Virtual Meeting

The American Heart Association Science Sessions will be a fully virtual event taking place November 13-15, 2021 and will feature seven last-minute science sessions over 3 days.

The latest delays include new data from the landmark EMPEROR-Preserved trial of empagliflozin (Jardiance, Boehringer Ingelheim / Eli Lilly) in patients with HF with preserved ejection fraction; the PREPARE-IT 2 trial on ethyl icosapent (Vascepa, Amarin) as an outpatient treatment with COVID-19; and the Fitbit Heart Study, which will provide data on the detection of atrial fibrillation in patients using the Fitbit wearable device.

The AHA has announced the following last-minute scientific programming for the annual meeting:

Late-Breaking Science 1: Valves, Veins, and New Perspectives in Cardiothoracic Surgery

• Aortic valve replacement versus watchful waiting in severe asymptomatic aortic stenosis: the AVATAR trial
• Evaluating the Benefits of Concomitant Tricuspid Repair During Mitral Valve Surgery
• A randomized study of early coronary artery bypass graft surgery compared to standard surgery in patients with acute coronary syndromes treated with Ticagrelor (RAPID CABG)
• Efficacy and safety of an external support device for saphenous vein coronary bypass grafts: the VEST trial

Late-Breaking Science 2: Hypertension: Local, Global and Pandemic Impacts

• A remote hypertension and lipid program in 10,000 patients in a diverse healthcare network
• Disruption of blood pressure monitoring with the COVID-19 pandemic: a study of 24 U.S. health systems in the PCORnet blood pressure monitoring lab (BP Track)
• A cluster-randomized trial of a village doctor-led intervention on blood pressure control: China Rural Hypertension Control Project (CRHCP)

Late-breaking science 3: From prevention to intervention in atrial arrhythmias

• The Coffee and Real-Time Atrial-Ventricular Ectopia (CRAVE) Trial
• Dabigatran versus warfarin on cognitive outcomes of nonvalvular atrial fibrillation: results of the GIRAF trial
• Left posterior pericardiotomy reduces postoperative atrial fibrillation after cardiac surgery (PALACS)
• Results of adjuvant left atrial appendage ligation using LARIAT versus antral pulmonary vein isolation alone: ​​the AMAZE trial

Last Minute Science 4: Information Overload? Strive to improve care delivery through digital health and automated data

• Risk assessment and its impact on clinical decision-making and heart failure outcomes: the REVeAL-HF trial
• Detecting Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
• Testing for Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

Late-Breaking Science 5: Building on Treatment Foundations: Advances in Heart Failure Treatment

• Heart Failure with 50% Preserved Ejection Fraction – EMPEROR-Preserved Clinical Trial Results
• The Clinical Trial Impact of Canagliflozin on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF)
• Efficacy and Safety of Empagliflozin in Hospitalized Patients with Heart Failure: Main Results from the EMPULSE Trial
• Randomized trial of targeted transendocardial administration of mesenchymal precursor cells in high-risk chronic heart failure patients with reduced ejection fraction (DREAM-HF)

Last minute science 6: Fish oil, cocoa and cholesterol: recipes for CVD prevention?

• Icosapent Ethyl versus placebo on an outpatient basis with Covid-19: the main results of PREPARE-IT 2
• Key Findings from the Cocoa Supplements and Multivitamins (COSMOS) Study on Prevention of Cardiovascular Disease
• Clinical Safety, Pharmacokinetics, and LDL Cholesterol Reducing Efficacy of MK-0616, an Oral PCSK9 Inhibitor

Breaking News 7: New Drugs and New Drug Indications in Cardiovascular Disease

• Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial
• P2y12 inhibitors in non-critically ill hospitalized patients with Covid-19 (ACTIV-4A)
• Effect of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients with Uncontrolled Bleeding or Requiring Urgent Surgery on REVERSE-IT
• Milvexian for the prevention of venous thromboembolism after elective knee replacement surgery: the AXIOMATIC-TKR study